01 — The Text
What.
- Increases limit on copying commercial drugs from 4 to 20 times per month without FDA approval.
- Requires pharmacies and doctors to report annually if they compound copy drugs over 20 times monthly for out-of-state patients.
- Mandates regular inspections of large-scale facilities that bulk-compound drugs.
- Redefines what counts as a drug 'copy' — removes FDA's consideration of dosage strength and route of administration.
02 — The Stakes
So what?
- Pharmacies and compounders win more flexibility to make unregulated copies of existing drugs. Patients get cheaper alternatives to brand-name drugs.
- Drug manufacturers lose exclusive market control when pharmacies copy their products without FDA testing.
- Patients with unusual dosage needs may benefit, but quality oversight decreases since copies skip FDA safety review.
- Hospitals exempt from reporting; smaller pharmacies face new compliance costs.
03 — The Path
Now what?
- Bill passed Senate committee on 7/27/26 with amendments. Awaits full Senate vote — no timeline set yet.
- Senate can vote anytime; bill needs House passage and presidential signature to become law.
- Track progress at Congress.gov or contact your senator to express support or concerns.
Legislative History
Actions.
- Jul 27, 2026 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 524.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026 — Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Feb 5, 2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Feb 5, 2026 — Introduced in Senate